ChiCTR-IPR-17011233
尚未开始
/
/
/
2017-04-24
/
/
Autism Spectrum Disorder
對香港自閉症譜系兒童及其家庭進行正念訓練改善其健康狀况
對香港自閉症譜系兒童及其家庭進行正念訓練改善其健康狀况
The goals of this project are to 1) reduce public stigma towards people and families with ASD and to improve the wellbeing of people and families with ASD in Hong Kong; 2) to evaluate the acceptability and effectiveness of a mindfulness training programme for adolescents with ASD and their parents for the first time in Hong Kong. The objectives of this project are to: 1) improve public awareness of ASD in Hong Kong 2) improve social responsiveness and reduce problem behaviours of adolescents with ASD 3) reduce parental stress and improve parenting style of parents of adolescents with ASD 4) develop and improve the expertise of health professionals in providing mindfulness interventions for adolescents with ASD.
随机平行对照
探索性研究/预试验
After the baseline visit, participants will be randomly assigned to one of the treatment groups by using a list of computer-generated random numbers. This generation of random numbers and assignment will be performed by an independent statistician.
The participants and instructors by nature will be informed of the randomisation allocation results, however, the trained research assistant/associate who conducts the assessments and the statistician who conducts the data analysis will be kept blinded of the grouping.
FOOD AND HEALTH BUREAU, HONG KONG SAR
/
16
/
2017-07-05
2018-07-04
/
The inclusion criteria of participants for the training will be children aged 12 to 18 years who have received a diagnosis of Autism Spectrum Disorders (ASD) by a doctor and also one of their parents agrees to participate in the MYmind training. Furthermore, if the child is on medication for ASD, the parents should have confirmed that they do not intend to change the medication status of their child during the study period. Parents will be asked to bring a copy of the ASD diagnosis of their children from a clinical doctor, usually a psychiatrist, for confirmation of the ASD diagnosis during the interview before they attend the MYmind training programme.;
请登录查看The exclusion criteria will be: 1) being unable to communicate and understand Chinese language as the intervention will be conducted in Chinese; 2)having a medical condition rendering him/her to be incapable to participate in the study; 3) unwilling or unable to give consent; 4) having substance dependence within the past 6 months, or a history of mental retardation, borderline and antisocial personality disorder, chronic suicidal and self-injurious behavior; or 5) participating in another ongoing psychological intervention.;
请登录查看HEALTH CARE AND PROMOTION FUND
/
HEALTH CARE AND PROMOTION FUND的其他临床试验
JC School of Public Health and Primary Care, The Chinese University of Hong Kong的其他临床试验
- Personalised Lifestyle Medicine in Mid-life Project
- Effects of Behavioural Activation With Mindfulness and Physical Exercise (BAMPE) on Mental Health: A Randomized Controlled Trial
- Effects of stand-alone mindfulness practices for people with long COVID-19 symptoms: A randomized controlled trial
- 慢性腰背痛症者對靜觀治療的支付意願和偏好
- Online integrated mindfulness-meaning programme for depression and anxiety during COVID-19: A pilot randomized controlled trial
- 專科門診病人經驗調查 2018/19
- 對香港自閉症譜系兒童及其家庭進行正念訓練改善其健康狀况
- 正念认知疗法治疗自杀幸存者预试验
- 兩個临床證據質量評估工具的可靠性比較:隨機對照試驗
- 以社區為基礎的隊列研究 - 使用全自動視網膜圖像分析(ARIA)來評估中風風險與生活方式的關系
- Electroacupuncture and Wrist Splinting for Carpal Tunnel Syndrome: A Randomized Trial in Primary Care Setting
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

